Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-001

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMelissa BurnsVKVictoria KochSCSarah M. Cronholm

Discussion

Loading...

Member takes

Overview

Analysis shows 4-year event-free survival of 96.3% for low MRD in non-adverse T-ALL, suggesting better risk stratification is needed.

Key Points

  • Overall survival improved significantly for children with T-ALL treated under DFCI protocol.
  • MRD assessment via next generation sequencing identified crucial prognostic variables for therapy effectiveness.
  • Doxorubicin and dexamethasone were integral to induction chemotherapy strategies across diverse patient risks.
  • Novel treatment interventions are required for very high-risk T-ALL patients experiencing adverse biology.

Cite This Study

Burns et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d400https://doi.org/10.1182/blood-2025-644
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy2025 · 4 citations
  2. 2Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium2025 · 1 citations
  3. 3Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol2025
  4. 4T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults2025 · 2 citations
  5. 5High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)2025 · 2 citations